Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCryst Pharmaceuticals has received another $2m from the National Institute of Allergy and Infectious Diseases (NIAID) to continue development of BCX4430 to treat hemorrhagic virus diseases.
Subscribe to our email newsletter
The NIAID has exercised two additional options under its contract with BioCryst, which provides for GMP drug substance and drug product manufacture of BCX4430.
So far, BioCryst has received about $20m to develop BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease.
If all awards are exercised, the full value of the contract is expected to be $26.3m.
The project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
The objective of the company’s BSAV research program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to health and national security.
BCX4430 is being developed by the company in collaboration with US Government Agencies following the Animal Rule regulatory pathway.
The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has showed broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.